ChartRow logo
ABVX
Abivax SA American Depositary SharesStock · Health Care
$114.71+0.59%
as of market close, Sep 4, 2026
☾ AH $114.80 +0.00%
PeersMRNALLYJNJUNHMRKABBV

ABVX financial statements

The full income statement, balance sheet, and cash-flow statement for Abivax SA American Depositary Shares (ABVX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2021-12 16.8M2022-12 22.3M2023-12 62.9M2024-12 63.3M2025-12 69.5M+315.0% over 4 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

As-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Research & development201M+26.9%159M+42.1%112M+119.8%50.8M-10.2%56.5M
Operating income-278M-48.8%-187M-35.9%-138M-102.1%-68.2M-39.2%-49.0M
Interest expense126M+587.8%18.4M-39.0%30.1M+308.3%7.38M+75.3%4.21M
Pre-tax income-374M-96.0%-191M-19.4%-160M-150.2%-63.9M-27.2%-50.2M
Income tax6.62M0.000.000.000.00
Net income-380M-99.4%-191M-19.4%-160M-150.2%-63.9M-27.2%-50.2M
-$5.47-80.4%-$3.03+18.3%-$3.71-11.0%-$3.34-2.8%-$3.25
EPS (basic)-$5.47-80.4%-$3.03+18.3%-$3.71-11.0%-$3.34-2.8%-$3.25
Weighted-avg shares (basic)69.5M+10.3%63.0M+46.4%43.1M+125.6%19.1M+23.5%15.5M
Weighted-avg shares (diluted)69.5M+10.3%63.0M+46.4%43.1M+125.6%19.1M+23.5%15.5M
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
648M+263.8%178M-43.8%317M+720.6%38.6M-55.0%85.8M
Cash & equivalents607M+303.5%150M-46.1%279M+870.6%28.7M-58.3%69.0M
686M+220.7%214M-40.9%362M+349.5%80.5M-35.1%124M
Goodwill21.6M+12.6%19.2M-5.8%20.4M+3.8%19.6M-46.0%36.4M
Total non-current assets38.9M+7.9%36.0M-20.8%45.5M+8.4%42.0M+9.5%38.3M
Total current liabilities74.0M-24.5%98.0M-2.3%100M+83.0%54.9M+49.7%36.7M
535M+1163.3%42.3M-80.5%217M+2730.7%7.66M-74.0%29.5M
Total equity incl. non-controlling535M+1163.3%42.3M-80.5%217M+2730.7%7.66M-74.0%29.5M
Common shares issued78.5M+24.0%63.3M+0.7%62.9M+182.0%22.3M+33.1%16.8M
Common shares outstanding63.3M+0.7%62.9M+182.1%22.3M+33.1%16.8M
Shares outstanding (cover)78.5M+24.0%63.3M+0.7%62.9M
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Cash from operations-182M-9.4%-167M-58.7%-105M-85.2%-56.7M-6.4%-53.3M
Acquisitions0.000.000.000.000.00
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued733M0.00-100.0%382M+686.3%48.6M-41.0%82.4M
Common stock repurchased0.000.000.000.000.00
Dividends paid0.000.000.000.000.00
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap9.38B+1922.0%464M+127.0%204M
P/B17.5×+60.1%11.0×-58.9%26.7×
Source filing20-F20-F20-F10-K10-K

About this data

Source: ABVX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ABVX filings on SEC EDGAR → Not investment advice.